Long-term survival with oral azacitidine for patients with acute myeloid leukemia in first remission after chemotherapy: Updated results from the randomized, placebo-controlled, phase 3 QUAZAR AML-001 trial

Andrew H. Wei; Hartmut Döhner; Hamid Sayar; Farhad Ravandi; Pau Montesinos; Hervé Dombret; Dominik Selleslag; Kimmo Porkka; Jun Ho Jang; Barry Skikne; C. L. Beach; Thomas Prebet; George Zhang; Alberto Risueño; Manuel Ugidos; Wendy L. See; Daniel Menezes; Gail J. Roboz

doi:10.1002/ajh.26847

Long-term survival with oral azacitidine for patients with acute myeloid leukemia in first remission after chemotherapy: Updated results from the randomized, placebo-controlled, phase 3 QUAZAR AML-001 trial

Andrew H. Wei, Hartmut Döhner, Hamid Sayar, Farhad Ravandi, Pau Montesinos, Hervé Dombret, Dominik Selleslag, Kimmo Porkka, Jun Ho Jang, Barry Skikne, C. L. Beach, Thomas Prebet, George Zhang, Alberto Risueño, Manuel Ugidos, Wendy L. See, Daniel Menezes, Gail J. Roboz

Leukemia

Research output: Contribution to journal › Letter › peer-review

2 Scopus citations

Original language	English (US)
Pages (from-to)	E84-E87
Journal	American journal of hematology
Volume	98
Issue number	4
DOIs	https://doi.org/10.1002/ajh.26847
State	Published - Apr 2023

ASJC Scopus subject areas

Hematology

Access to Document

10.1002/ajh.26847

Cite this

Wei, A. H., Döhner, H., Sayar, H., Ravandi, F., Montesinos, P., Dombret, H., Selleslag, D., Porkka, K., Jang, J. H., Skikne, B., Beach, C. L., Prebet, T., Zhang, G., Risueño, A., Ugidos, M., See, W. L., Menezes, D., & Roboz, G. J. (2023). Long-term survival with oral azacitidine for patients with acute myeloid leukemia in first remission after chemotherapy: Updated results from the randomized, placebo-controlled, phase 3 QUAZAR AML-001 trial. American journal of hematology, 98(4), E84-E87. https://doi.org/10.1002/ajh.26847

Long-term survival with oral azacitidine for patients with acute myeloid leukemia in first remission after chemotherapy: Updated results from the randomized, placebo-controlled, phase 3 QUAZAR AML-001 trial. / Wei, Andrew H.; Döhner, Hartmut; Sayar, Hamid et al.
In: American journal of hematology, Vol. 98, No. 4, 04.2023, p. E84-E87.

Research output: Contribution to journal › Letter › peer-review

Wei, AH, Döhner, H, Sayar, H, Ravandi, F, Montesinos, P, Dombret, H, Selleslag, D, Porkka, K, Jang, JH, Skikne, B, Beach, CL, Prebet, T, Zhang, G, Risueño, A, Ugidos, M, See, WL, Menezes, D & Roboz, GJ 2023, 'Long-term survival with oral azacitidine for patients with acute myeloid leukemia in first remission after chemotherapy: Updated results from the randomized, placebo-controlled, phase 3 QUAZAR AML-001 trial', American journal of hematology, vol. 98, no. 4, pp. E84-E87. https://doi.org/10.1002/ajh.26847

@article{115fe629ba334aa49635de92c888530a,

title = "Long-term survival with oral azacitidine for patients with acute myeloid leukemia in first remission after chemotherapy: Updated results from the randomized, placebo-controlled, phase 3 QUAZAR AML-001 trial",

author = "Wei, {Andrew H.} and Hartmut D{\"o}hner and Hamid Sayar and Farhad Ravandi and Pau Montesinos and Herv{\'e} Dombret and Dominik Selleslag and Kimmo Porkka and Jang, {Jun Ho} and Barry Skikne and Beach, {C. L.} and Thomas Prebet and George Zhang and Alberto Risue{\~n}o and Manuel Ugidos and See, {Wendy L.} and Daniel Menezes and Roboz, {Gail J.}",

note = "Funding Information: The authors thank the patients, families, investigators, staff, and clinical study teams who participated in the QUAZAR AML‐001 trial. All authors contributed to and approved the manuscript for submission. Writing and editorial support were provided by Korin Albert, PhD, of Excerpta Medica, funded by Bristol Myers Squibb. ",

year = "2023",

month = apr,

doi = "10.1002/ajh.26847",

language = "English (US)",

volume = "98",

pages = "E84--E87",

journal = "American journal of hematology",

issn = "0361-8609",

publisher = "Wiley-Liss Inc.",

number = "4",

}

TY - JOUR

T1 - Long-term survival with oral azacitidine for patients with acute myeloid leukemia in first remission after chemotherapy

T2 - Updated results from the randomized, placebo-controlled, phase 3 QUAZAR AML-001 trial

AU - Wei, Andrew H.

AU - Döhner, Hartmut

AU - Sayar, Hamid

AU - Ravandi, Farhad

AU - Montesinos, Pau

AU - Dombret, Hervé

AU - Selleslag, Dominik

AU - Porkka, Kimmo

AU - Jang, Jun Ho

AU - Skikne, Barry

AU - Beach, C. L.

AU - Prebet, Thomas

AU - Zhang, George

AU - Risueño, Alberto

AU - Ugidos, Manuel

AU - See, Wendy L.

AU - Menezes, Daniel

AU - Roboz, Gail J.

N1 - Funding Information: The authors thank the patients, families, investigators, staff, and clinical study teams who participated in the QUAZAR AML‐001 trial. All authors contributed to and approved the manuscript for submission. Writing and editorial support were provided by Korin Albert, PhD, of Excerpta Medica, funded by Bristol Myers Squibb.

PY - 2023/4

Y1 - 2023/4

UR - http://www.scopus.com/inward/record.url?scp=85147494639&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85147494639&partnerID=8YFLogxK

U2 - 10.1002/ajh.26847

DO - 10.1002/ajh.26847

M3 - Letter

C2 - 36655608

AN - SCOPUS:85147494639

SN - 0361-8609

VL - 98

SP - E84-E87

JO - American journal of hematology

JF - American journal of hematology

IS - 4

ER -

Long-term survival with oral azacitidine for patients with acute myeloid leukemia in first remission after chemotherapy: Updated results from the randomized, placebo-controlled, phase 3 QUAZAR AML-001 trial

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this